The result revealed that patients with RCC and high TMIGD1-, moesin- or ezrin- expressing tumors had significantly better median overall survival compared with those with low TMIGD1-expressing tumors (Fig. 7A-C). This evidence concerns the gene TMIGD1 and renal cell carcinoma.